Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y - Ern Qtrly Grth -
Income -26.92M Forward P/E - EPS next Y 88.50% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 2.00 Quick Ratio 20.17 Shares Outstanding 21.38M 52W Low Chg 9.00%
Insider Own 0.06% ROA - Shares Float 10.49M Beta -
Inst Own 0.18% ROE - Shares Shorted/Prior 572.64K/1.04M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 42.67
Oper. Margin -372.60% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
12/04/23 Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
11/28/23 Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
11/22/23 Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
11/13/23 Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
11/10/23 Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
10/24/23 Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
10/18/23 Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
09/27/23 Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
08/29/23 ‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
08/21/23 Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
08/15/23 Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
07/20/23 Sagimet Biosciences Announces Leadership Changes
07/13/23 Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
SGMT Chatroom

User Image johnnyutah007 Posted - 1 day ago

$SGMT looks to be on its way to 5

User Image fda_tracker Posted - 1 day ago

$SGMT Phase 2 trial w/est Dec completion date NCT03808558: https://www.clinicaltrials.gov/study/NCT03808558 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image G101SPM Posted - 1 day ago

$SGMT $4.06 last bid. DAC $5.48 latest $3.69 (11.27.23). EXIT 22.00 - LH). UPDATE: Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, announced its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual fireside chat at 12:00 p.m. ET / 9:00 a.m. PT on Wednesday, December 6, 2023.

User Image G101SPM Posted - 2 days ago

$SGMT $3.845 +0.05. DAC $3.69 (11.27.23). EXIT $22.00 LH play. UPDATE: Sagimet Biosciences Inc.(SGMT) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual fireside chat at 12:00 p.m. ET / 9:00 a.m. PT on Wednesday, December 6, 2023.

User Image UltraAlgo Posted - 5 days ago

$SGMT Sell rating from 4 signals, 15-min chart 💸 Learn More ultraalgo.com/stock-trading-ideas https://i.redd.it/a08c6hmt1y2c1.png

User Image MattWalk1987 Posted - 11/29/23

$COCH $SGMT $LICY $ALDX Green Green Green Green Green 🚀🚀

User Image kthart Posted - 11/29/23

$SGMT can you say coiled spring?

User Image StockAutomatePro Posted - 11/29/23

$SGMT The chart is indicating a positive future for the stock. We alerted the BUY signal at $2.48 and we were able to close this one with profit at $4🤙

User Image Stock_Titan Posted - 11/28/23

$SGMT Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit https://www.stocktitan.net/news/SGMT/sagimet-biosciences-announces-oral-presentation-of-preclinical-eyhepp2y6kea.html

User Image G101SPM Posted - 11/27/23

$SGMT $3.68 -0.42. BUY/ADD 2X TO LONG POSITION. DAC $5.48 prior $8.725 (9.28.23). EXIT $22.00. UPDATE: (1) Announced upcoming 35th Annual Piper Sandler Healthcare Conference being held in New York. David Happel, Chief Executive Officer, and Eduardo Bruno Martins, M.D., D.Phil., Chief Medical Officer, are scheduled to participate in a fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Wednesday, November 29, 2023. (2) On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024, (3) Two abstracts, including late-breaker, accepted at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023 and (4) Enrollment of 120 patients in Phase 3 registrational trial of denifanstat in recurrent glioblastoma (GBM) announced by license partner, Ascletis.

User Image MrEggo Posted - 11/27/23

$SGMT need a saucer to set this on.

User Image jaz0099 Posted - 11/27/23

$SGMT presentation is at 2:30 PM (central time) on November 29. I have a feeling they have good news to share. Just my opinion.

User Image MrEggo Posted - 11/27/23

$SGMT train isn’t stopping anytime soon. Hop on.

User Image GloriaPruitt Posted - 11/27/23

$SGMT $ASTS $KOD Started trading over 4 months ago and I lost $3K. Now I've made over $177K+ profits after joining their chat room and using their alerts.. Highly recommended! It's free joining,<<👉 top-stocks-winning-great.profitablestocks.vip/

User Image StockAutomatePro Posted - 11/25/23

$SGMT Positive news for stockholders chart shows upward trend. We alerted the BUY signal at $2.5 and we were able to close this one with profit at $4.1 📊 See more details at StockAutomate.com

User Image GoldPannin Posted - 11/25/23

$SGMT

User Image GoldPannin Posted - 11/25/23

$SGMT

User Image StarTrader1928 Posted - 11/24/23

$SGMT Congrats to all the “trading at a discount to cash” club members. I am complete with this trade today. Two trades that I still am accumulating and looking for huge moves are $VLCN and $VHC

User Image MrEggo Posted - 11/24/23

$SGMT continues to be a fantastic play. Anything under $5 and you’re golden I believe. LT this thing is going much, much higher.

User Image StockAutomatePro Posted - 11/24/23

$SGMT The chart is indicating a favorable market for the stock. We alerted the BUY signal at $2.5 and we were able to close this one with profit at $3.68 💯 See more details at StockAutomate.com

User Image MrEggo Posted - 11/22/23

$SGMT up almost 30% since I called it, still has a TON of room to run. Not one to cross post but I feel like letting some folks that were in $CDIO $SGD $TTOO with me know about this one, do your own DD.

User Image RollingDollar Posted - 11/22/23

$SGMT

User Image Stock_Titan Posted - 11/22/23

$SGMT Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference https://www.stocktitan.net/news/SGMT/sagimet-biosciences-to-present-at-the-35th-annual-piper-sandler-5lur44veqhgx.html

User Image Last10K Posted - 11/21/23

$SGMT just filed with the SEC a Event for Officers https://last10k.com/sec-filings/SGMT/0001104659-23-120365.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=SGMT

User Image cctranscripts Posted - 11/21/23

Sagimet Biosciences Inc.'s President & CEO just picked up 624,910 shares https://www.conferencecalltranscripts.org/summary/?id=12728455 $SGMT

User Image cctranscripts Posted - 11/21/23

Sagimet Biosciences Inc.'s Executive Chairman just picked up 150,750 shares https://www.conferencecalltranscripts.org/summary/?id=12728453 $SGMT

User Image EarningsInsider Posted - 11/21/23

Sagimet Biosciences Inc. Files SEC Form 8-K $SGMT https://www.marketbeat.com/stocks/NASDAQ/SGMT/sec-filings/

User Image MarketBeatInsiderTrades Posted - 11/21/23

Sagimet Biosciences CEO David Happel Buys $1,386.50 in $SGMT www.marketbeat.com/stocks/NASDAQ/SGMT/insider-trades/

User Image StockAutomatePro Posted - 11/21/23

$SGMT The chart is indicating an upward trend for the stock. We alerted the BUY signal at $3.13 and we were able to close this one with profit at $3.01 💯 See more details at StockAutomate.com

User Image CEOBuysDisclosures Posted - 11/21/23

$SGMT CEO purchased 590 shares at $2.35 for a total of $1,387. Happel David now owns 590 shares. https://ceo-buys.com

Analyst Ratings
JMP Securities Market Outperform Dec 5, 23
TD Cowen Outperform Aug 8, 23
Piper Sandler Overweight Aug 8, 23
JMP Securities Market Outperform Aug 8, 23
Goldman Sachs Buy Aug 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23